step · intermediate · partly written
High-throughput screening
One step of the screening cascade walk-through, from disease to clinic.
What is done
Robots deliver a tiny, identical amount of each compound to every well of a plate and an assay reads the result. The automation sets the dose and timing; the readout (enzyme, cell, reporter or image) measures. Dispensing is by pin tool, tips or acoustic droplets; a vendor claims its acoustic dispenser ejects up to 700 drops per second. In the STK33 kinase screen each 1536-well received 2.5 nL of 10 mM compound. Plate quality is checked with controls using the Z-prime statistic. 123
Reported, not yet replicated
Costs
Same public prices as hit discovery: FY25 internal rates of $1.00 per well (small-molecule 384-well) or $2.50 (imaging or flow) with a $7,500 or $10,000 setup fee at one academic core, and a 2020 sheet pricing a 25,000-compound biochemical screen at $7,041 internal. No instrument list price or per-well consumable cost was found on an opened page; the vendor page directs to a quote form. 453
Reported, not yet replicated
Proves
That the assay separated its positive and negative controls on that plate, and that compounds shifted the signal relative to them. The scale shows what the step is for: Pfizer went from 800 compounds a week in 1986 to 7,200 a week by 1989 in 96-well plates, and the NIH Chemical Genomics Center robot ran libraries over 100,000 compounds and produced over 6 million concentration-response curves from over 120 assays in three years (abstracts read). 672
Reported, not yet replicated
Cannot prove
That a hit is real: a good Z-prime says the controls are separated, not that the hits are genuine. The way a compound is moved can change its measured potency. One study reported that tip-based serial dilution and acoustic dispensing gave EphB4 IC50 values differing by orders of magnitude (abstract read; disputed and not independently replicated in what was opened), and a statistical analysis found that routine robotic dilution steps can add large imprecision and some bias. 289
Reported, not yet replicated
Assays
Regulators require
No regulation read for this atlas says how hits or leads must be found. The first document the regulator requires is the investigational new drug application, whose pharmacology and toxicology section is built from laboratory-animal or in vitro studies on which the sponsor concludes it is reasonably safe to begin trials (21 CFR 312.23(a)(8)). Discovery data reaches the regulator only as the sponsor's own supporting evidence. This is our reading of the rule, not a statement in it. 10
Our inference
ML role
Does: image-based profiles feed models that predict activity; in one study structures, Cell Painting and L1000 profiles each predicted activity well in 6 to 10% of 270 assays and 21% combined. Cannot: similarity in a profile is not binding, and a cell-count-only baseline scores unexpectedly well on common benchmarks, so a high score can reflect cytotoxicity. No machine-learning method for the dispensing step itself was found. 1112
Reported, not yet replicated
Reports
- a record that is not published here
- a record that is not published here
Scenarios
Modality notes
Antisense screens are sequence walks, not compound libraries
An antisense screen tests many sequences tiled along one RNA target; the SMN2 screen cited is an example. This restates the modality record and was not re-read at the paper level for plate formats. 1314
See: Antisense oligonucleotide (ASO)
Our inference
Still open here
- Instrument and per-well consumable prices were not found on any opened page.
- Hit rates by assay format across programmes were not compiled; only the STK33 numbers are written.
Linked from
Sources
- PubChem BioAssay AID 2661: STK33 primary screen (ADP-Glo). PubChem. database, not peer reviewed; opened 2026-11-17 all records citing this
- Zhang, J.H., Chung, T.D.Y., Oldenburg, K.R.. Zhang, Chung and Oldenburg 1999: a simple statistical parameter for HTS assay validation (Z-prime). Journal of Biomolecular Screening (record via Europe PMC) (1999). paper; opened 2026-11-17 all records citing this
- Echo acoustic liquid handlers (Beckman Coulter). Beckman Coulter. vendor-page, not peer reviewed; opened 2026-11-17 all records citing this
- Ohio State University High Throughput Screening Core: cost structure (FY25). Ohio State University (2025). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
- MSU Assay Development and Drug Repurposing Core recharge rates (file dated 2020-05-27). Michigan State University (2020). report, not peer reviewed; opened 2026-11-17 all records citing this
- Pereira, D.A., Williams, J.A.. Pereira and Williams 2007: origin and evolution of high throughput screening (Pfizer). Europe PMC record (2007). review; opened 2026-11-17 all records citing this
- Michael, S., et al.. Michael et al. 2008: robotic platform for quantitative high-throughput screening (NCGC). Europe PMC record (2008). paper; opened 2026-11-17 all records citing this
- Ekins, S., Olechno, J., Williams, A.J.. Ekins, Olechno and Williams 2013: dispensing processes impact apparent biological activity, PLoS One. PLoS One (record via Europe PMC) (2013). paper; opened 2026-11-17 all records citing this
- Hanson, S.M., Ekins, S., Chodera, J.D.. Hanson, Ekins and Chodera 2015: bootstrap analysis of dilution and dispensing imprecision. Journal of Computer-Aided Molecular Design (record via Europe PMC) (2015). paper; opened 2026-11-17 all records citing this
- US Food and Drug Administration. IND content and format (21 CFR 312.23). Electronic Code of Federal Regulations, Title 21, Part 312 (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Moshkov et al.. Predicting compound activity from phenotypic profiles and chemical structures (Moshkov et al. 2023), Europe PMC listing. Europe PMC listing (2023). paper; opened 2026-11-17 all records citing this
- Seal et al.. Counting cells can accurately predict small-molecule bioactivity benchmarks (Seal et al., Nature Communications 2026). Nature Communications (2026). paper; opened 2026-11-17 all records citing this
- Hua, Y., et al.. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. American Journal of Human Genetics (2008). paper; opened 2026-11-17 all records citing this
- Egli, M., Manoharan, M.. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Research (2023). review; opened 2026-11-17 all records citing this
History of this record (5)
This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Order
- 6
- Stage
- hit-discovery
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/cascade/high-throughput-screening.json